| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
MNAC13 (200-300 μg/mL, 1 h) specifically binds to TrkA and inhibits NGF-dependent signaling in TrkA-overexpressing 3T3 cells [1]. MNAC13 (4 μg/mL, 4 days) effectively blocks NGF-induced PC12 cell survival and axonal growth [2]. MNAC13 (2 or 20 ng/mL) specifically binds to TrkA immunoadhesives but not to TrkB in TrkA-BALB/C 3T3 cells [2].
|
|---|---|
| ln Vivo |
MNAC13 (0.9–60 μg; intraperitoneal or subcutaneous injection; single dose; 18 hours before formalin test) significantly reduced inflammatory pain in male CD1 mice injected with 5% formalin solution [1]. MNAC13 (30–70 μg; intraperitoneal injection; once daily; from day 3 to day 10) significantly reduced neuropathic pain in male CD1 mice with chronic restraint injury (CCI) and had a sustained analgesic effect [1]. MNAC13 (1 μg; intraperitoneal injection; single dose; 15 minutes before test) in combination with opioids had a significant synergistic analgesic effect in male CD1 mice injected with 5% formalin solution [1]. In Wistar rats injected with MNAC13 hybridoma cells, MNAC13 had a more significant and longer-lasting TrkA blocking effect on basal forebrain cholinergic neurons (BFCNs) than NGF blocking effect [2].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: 3T3 cells overexpressing TrkA Tested Concentrations: 200-300 μg/mL Incubation Duration: 1 hour Experimental Results: Significantly inhibited the phosphorylation of TrkA and the phosphorylation level of downstream signaling molecule PLCγ1. |
| Animal Protocol |
Animal/Disease Models:CD1 male mice (30-40 g) injected with 5% formalin solution [1]
Doses: 0.9, 1.875, 3.75, 7.5, 15, 30 and 60 μg Route of Administration: Subcutaneous injection (sc) 0.9, 1.875, 3.75, 7.5, 15, 30 and 60 μg; Intraperitoneal injection (ip) 15 μg Experimental Results: Significantly reduced late-stage licking behavior and was also effective against early pain at a dose of 15 μg. Animal/Disease Models:CCI CD1 male mice (30-40 g)[1] Doses: 30, 50 and 70 μg Route of Administration: Intraperitoneal injection (ip); once daily from day 3 to day 10 Experimental Results: Significantly reduced mechanical hyperalgesia with a long-lasting effect. Animal/Disease Models:CD1 male mice (30-40 g) injected with 5% formalin solution [1] Doses: 1 μg; used in combination with morphine (1 mg/kg) or fentanyl (5 μg/kg) Route of Administration: Intraperitoneal injection (ip); 15 minutes before the test Experimental Results: Produced significant synergistic analgesia. Acting on the central nervous system, naloxone failed to reverse this synergistic effect. |
| References |
|
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
